Immunocore Holdings PLC Schedule 13G passive stakes

Wellington Management Group LLP and its affiliates have reported a significant beneficial ownership stake in Immunocore Holdings plc, holding 11.6% of the common stock as of June 30, 2026.

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 8.8% of Immunocore Holdings PLC's common stock as of June 30, 2026.

Vestal Point Capital, LP and Ryan Wilder have filed a Schedule 13G reporting a 5.5% beneficial ownership stake in Immunocore Holdings plc.

T. Rowe Price Investment Management, Inc. has reported an updated beneficial ownership of 6.0% in ImmunoCore Holdings PLC-ADR, holding 3,041,904 shares.

Bellevue Group AG and its subsidiary Bellevue Asset Management AG have reported a 5.6% beneficial ownership stake in Immunocore Holdings plc.

Tang Capital Management and Kevin Tang reported a combined beneficial ownership of 5.2% in Immunocore Holdings plc, totaling 2,605,608 American Depositary Shares.

Eli Lilly and its subsidiary, Eli Lilly S.A., have reported zero beneficial ownership in Immunocore Holdings plc, indicating a complete divestment of their previous stake.

PRIMECAP Management Co. reports an increased beneficial ownership of 7.51% in Immunocore Holdings plc ADRs.

Wellington Management Group LLP and its affiliates have reported a 10.2% beneficial ownership stake in Immunocore Holdings plc common stock as of July 31, 2025.

Wellington Management Group LLP and its affiliates report a continued 9.1% beneficial ownership stake in Immunocore Holdings plc common stock.

T. Rowe Price Investment Management, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 14.1% in Immunocore Holdings PLC-ADR as of March 31, 2025.

Wellington Management Group LLP and its affiliated entities have reported a 13.0% beneficial ownership stake in Immunocore Holdings plc, held for investment purposes as of March 31, 2025.

Dr. Bahija Jallal, a key individual at Immunocore Holdings plc, has disclosed beneficial ownership of 8.2% of the company's ordinary shares as of December 31, 2024.

PRIMECAP Management Co./CA/ has disclosed a 5.33% beneficial ownership stake in Immunocore Holdings plc, holding 2,668,550 American Depositary Receipts (ADRs) as of December 31, 2024.